As of 2026-04-22, the Relative Valuation of Editas Medicine Inc (EDIT) is (19.83) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.30 USD, the upside of Editas Medicine Inc based on Relative Valuation is -700.9%.
The range of the Relative Valuation is (14.95) - (22.31) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.1x - 13.6x | 9.6x |
| Forward P/E multiples | 9.1x - 20.6x | 14.6x |
| Fair Price | (14.95) - (22.31) | (19.83) |
| Upside | -553.0% - -776.0% | -700.9% |
| Date | P/E |
| 2026-04-21 | -2.02 |
| 2026-04-20 | -2.18 |
| 2026-04-17 | -2.13 |
| 2026-04-16 | -2.05 |
| 2026-04-15 | -2.06 |
| 2026-04-14 | -2.07 |
| 2026-04-13 | -1.96 |
| 2026-04-10 | -1.80 |
| 2026-04-09 | -1.77 |
| 2026-04-08 | -1.69 |
| 2026-04-07 | -1.68 |
| 2026-04-06 | -1.66 |
| 2026-04-02 | -1.63 |
| 2026-04-01 | -1.60 |
| 2026-03-31 | -1.51 |
| 2026-03-30 | -1.36 |
| 2026-03-27 | -1.36 |
| 2026-03-26 | -1.42 |
| 2026-03-25 | -1.42 |
| 2026-03-24 | -1.38 |
| 2026-03-23 | -1.47 |
| 2026-03-20 | -1.43 |
| 2026-03-19 | -1.44 |
| 2026-03-18 | -1.44 |
| 2026-03-17 | -1.50 |
| 2026-03-16 | -1.55 |
| 2026-03-13 | -1.49 |
| 2026-03-12 | -1.55 |
| 2026-03-11 | -1.63 |
| 2026-03-10 | -1.61 |
| 2026-03-09 | -1.42 |
| 2026-03-06 | -1.22 |
| 2026-03-05 | -1.16 |
| 2026-03-04 | -1.34 |
| 2026-03-03 | -1.25 |
| 2026-03-02 | -1.31 |
| 2026-02-27 | -1.35 |
| 2026-02-26 | -1.33 |
| 2026-02-25 | -1.30 |
| 2026-02-24 | -1.29 |
| 2026-02-23 | -1.16 |
| 2026-02-20 | -1.09 |
| 2026-02-19 | -1.11 |
| 2026-02-18 | -1.05 |
| 2026-02-17 | -1.06 |
| 2026-02-13 | -1.08 |
| 2026-02-12 | -1.03 |
| 2026-02-11 | -1.08 |
| 2026-02-10 | -1.09 |
| 2026-02-09 | -1.11 |